二尖瓣修复与替换术后30天再入院的原因、危险因素与费用
基于美国全国再入院数据库2010至2014年76,342例成人二尖瓣手术患者,30天再入院率为17.0%,替换术再入院率(20.7%)高于修复术(13.1%)。再入院独立预测因素包括住院≥8天、慢性肺病、慢性肾病及低手术量医院,再入院最常见原因为心衰、心律失常和呼吸系统诊断。
要点
- 二尖瓣术后30天再入院率17.0%,替换术高于修复术(20.7% vs 13.1%)
- 住院≥8天、慢性肺病、慢性肾病及低手术量医院为再入院独立预测因素
- 再入院最常见病因为心衰(21.4%)、心律失常(17.0%)和呼吸系统诊断(15.0%)
核心结论
- 近五分之一的二尖瓣手术患者30天内再入院,低手术量医院与再入院强相关,且再入院负担较多落在非原手术医院。
研究设计与样本
- 回顾性队列研究,数据来自美国全国再入院数据库2010至2014年,纳入76,342例接受二尖瓣修复或替换的成人患者。
主要发现
- 30天再入院率为17.0%,替换术再入院率20.7%显著高于修复术13.1%(P < .001)。
- 修复与替换术后再入院的显著独立预测因素均包括住院时间≥8天、慢性肺病、慢性肾病及低医院二尖瓣手术量。
- 再入院至非原手术医院占全部再入院的26.6%。
- 再入院最常见指征为心衰(21.4%)、心律失常(17.0%)、呼吸系统诊断(15.0%)和感染(10.2%)。
- 每次再入院平均费用为15,397美元,再入院患者中再入院费用占该次诊疗总费用的17.8%。
临床怎么用
- 对二尖瓣术后患者应关注住院时间≥8天、合并慢性肺病或慢性肾病者,加强出院前评估与随访以降低再入院风险。
- 低手术量医院应重视二尖瓣手术的再入院负担,可通过优化围术期管理及出院后衔接改善 quality of care。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postsurgical readmissions are an increasingly scrutinized marker of health care quality. We sought to estimate the risk factors and costs associated with readmissions after mitral valve (MV) surgery in a large, nationally representative cohort. METHODS: Adult patients undergoing MV repair or replacement were queried from the National Readmissions Database from 2010 to 2014. Data were collected on the prevalence and indications for readmission within 30 days as well as the hospital-, procedure, and patient-level risk factors as determined by multivariable logistic regression. RESULTS: Among 76,342 patients undergoing MV surgery, the rate of 30-day readmission was 17.0%. Those undergoing replacement procedures had significantly higher readmission rates (20.7% vs 13.1%; P < .001) compared with repair. Significant independent predictors of readmission after both MV repair and replacement included length of stay ≥8 days, chronic lung disease, chronic renal disease, and low hospital procedural volume for MV surgery. Readmissions to nonindex hospitals accounted for 26.6% of all readmissions. The most common indications for readmission were heart failure (21.4%), arrhythmia (17.0%) and respiratory diagnoses (15.0%), and infections (10.2%). The mean cost per readmission was $15,397, and among readmitted patients, the cost of readmission accounted for 17.8% of the total cost of the episode of care. CONCLUSIONS: Nearly 1 in 5 patients undergoing MV surgery are readmitted within 30 days. Treatment at a low-volume center was strongly associated with readmission, and much of the readmission burden falls on nonindex hospitals. Further characterization of readmissions may improve the quality of care associated with MV surgery.
引用
- Goel NJ, Iyengar A, Kelly JJ, et al. Causes, Risk Factors, and Costs of 30-Day Readmissions After Mitral Valve Repair and Replacement. Ann Thorac Surg. 2019. PMID: 31479638. doi:10.1016/j.athoracsur.2019.07.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。